

CURRICULUM VITAE

Elaine E. Weiner, M.D.
Assistant Professor, Department of Psychiatry
University of Maryland School of Medicine

Date July 6, 2021

Contact Information

Business Address: Maryland Psychiatric Research Center (MPRC)
Outpatient Research Program
55 Wade Avenue
Catonsville, Maryland 21228

Business Phone Number: 410-402-7694
Fax: 410-402-7198
Email: eweiner@som.umaryland.edu

Education

1979-1983 B.A., Psychology with Special Honors and Distinction (Phi Beta Kappa), The
George Washington University, Washington, D.C.

1984-1988 M.D., UHS/The Chicago Medical School, Chicago, IL

Post Graduate Education and Training

1988-1993 Internship and Residency, Department of Psychiatry, University of Maryland
School of Medicine

Certifications

1994 American Board of Psychiatry and Neurology
2004 American Board of Psychiatry and Neurology
2015 American Board of Psychiatry and Neurology

Medical Licensure

1988 Active, Maryland

Employment History

Academic Appointments

8/1993-7/1994 Clinical Instructor, Department of Psychiatry, UMSOM
7/1994-present Assistant Professor, Department of Psychiatry, UMSOM

Other Employment

7/2000- 9/2005 Sinai Hospital/ Northwest Hospital Center- PRN Emergency Room
Coverage and weekend coverage, Levindale Psychiatric Unit, Baltimore,
Maryland

9/2005-12/2014 Key Point Health Services, Clozapine Clinic, Baltimore, MD

Professional Society Membership

1990-present American Psychiatric Association
1990-present Maryland Psychiatric Society

Honors and Awards

June 1998 Sandoz Award for Excellence in Psychiatry, UHS/The Chicago Medical School

Clinical Activities

Clinical Expertise

Areas of focus - Schizophrenia related disorders

- treatment resistance – implemented psychosocial treatments within group therapy context to address persistent positive and negative symptoms
- clozapine management:
 - managed two clozapine clinics for Key Point Health Services, furthering community access to this needed and underutilized treatment of last resort
 - provide consultations and initiation of clozapine therapy to community providers, patients and families (dosing, cross titration, discussing risks of life-threatening side effects, management of side effects with high morbidity)
 - obtained approximately 50% rate of clozapine usage; standard community setting is 10%
 - consultant to CHAMPION clozapine program which aims to increase the use of clozapine through education and easy access to consultation when needed by community prescribers
 - smoking cessation – developed programing to address the specific needs of this population, achieved clinic smoking rate of 30% which is significantly lower than the average for people with schizophrenia

Scope of Clinical Practice

2001-2008 Coordination of MPRC faculty rotation for PGY 2 Supervision, Spring
Grove Hospital Center (SGHC)

2001-2008 Coordination of MPRC faculty rotation SGHC weekly clinical case
conference

6/2020-present Medical Director, First Episode Clinic (FEC), MPRC

- Specialty program for people with a first episode of psychosis
- Outpatient clinical research program
- oversight of 100 patients weekly
- provide consultation to underserved areas
- leadership/administrative role
- 10% FTE

Administrative Service

Institutional Service

1997-1999 MPRC Schizophrenia Conference, organizer
 2006-2008 UMSOM Council Alternate and Representative
 1/2020-present MPRC Diversity, Equity, and Inclusion Committee

Local and National Service

Local Service

2003-2011 Reviewer, Maryland Board of Physicians Quality Assurance

National Service

2006-present Ad hoc Reviewer:
American Journal of Medical Genetics (1/yr)
CNS Spectrums (1/yr)
American Journal of Psychiatry (2/yr)
Schizophrenia Bulletin (1/yr)
Psychiatric Services (2/yr)
Nicotine and Tobacco Research (1/yr)
Journal of Clinical Psychiatry, (3/yr)
Lancet Psychiatry (1/yr)
Clinical Schizophrenia and Related Psychosis (5/yr)

Teaching Service

Undergraduate Student Teaching

2015-2016 Aisha Munawa, G/T Research Program, Howard County High School; currently premed student at UMD
 20017-2018 Emma Williamson, G/T Research Program, Howard County High; currently psychology major at UMD planning for UMSOM Masters’ program in clinical nurse leadership
 2019 Kirpa Singh summer volunteer following her freshman year at Berkeley, currently a Senior at Berkeley following a neuroscience path. Has been working as a research assistant at Kaiser Permanente Division of Research

Medical Student Teaching

1996-2008	Case Conference Discussant, Spring Grove Hospital Center
2010-present	Small group discussion leader, Sophomore Pathophysiology and Therapeutic/ Neuroscience Section (550/520,527) - 15-30 students per group; six-hours yearly.
2010-present	Small group discussion leader Physical Diagnosis and Interviewing/ Psychiatry Section (course SG-009 and 10) 2-4 students per group; 15-hour yearly.
2021-present	Mentor to Hafsa Raiz- Previous MPRC intern/ employee; Now MS 2; returned for a summer research project.

Resident Teaching

1995-2010	Case Conference Discussant, SGHC, monthly, two hours
1996-2016	PGY 4 Supervisor/ Mentor, as needed, face-to-face during rotation <ul style="list-style-type: none">• Robert Schloesser, 2014-2015; since 2016 he has been Associate Chief Medical Information Officer and Director of Point-of-Care Research & Innovation at Sheppard Pratt Health System and assistant professor of psychiatry at the University of Maryland School of Medicine.• Kelly Register Brown, 2013-2014; later did a Child/ Adolescent Fellowship; currently Assistant Professor and Medical Director of the Center for Autism Spectrum Disorders, Children's National Hospital and in private practice
	PGY 4 and Research Fellowship; as needed, face-to-face during rotation <ul style="list-style-type: none">• Juan Bustillo, M.D. 6/93-6/96; Post-Doctoral Research Fellows Current Position: Professor of Psychiatry, University of New Mexico School of Medicine• Celso Arango, M.D. 1/97-2/99; Post-Doctoral Research Fellows Current Position: Associate Professor of Psychiatry, Universidad Complutense, Madrid, Spain; Voluntary Faculty Associate Professor of Psychiatry, University of Maryland School of Medicine, Maryland Psychiatric Research Center• Cenk Tek, M.D., 2/98-1/2001; Psychiatry Residency Research Track Mentor: Current Position: Associate Professor of Psychiatry, Yale University Medical School; Director, Psychosis Program, Connecticut Mental Health Center, New Haven, Connecticut• David Potter, M.D., 7/2000-6/03; Psychiatry Residency Research Track Mentor: Current Position: private practice• Bernard Fischer, M.D., 7/04-6/07/07-6/09; Post-Doctoral Research Fellows T32 Research Fellowship, Maryland Psychiatric Research; Current Position: Assistant Professor of Psychiatry University of Maryland School of Medicine• William Keller, M.D., Psychiatry Residency Research Track Mentor: 7/07-6/11; Post-Doctoral Research Fellows: T32 Research Fellowship, Maryland Psychiatric Research Center, University of Maryland School of Medicine

- 1999-2010 PGY 2 Supervision, weekly, one-hour face to face during six-month Rotation
- Aleya Karim, 2002, currently in private practice at Dominion Hospital, Falls Church, VA
 - Brad Trommer, 2006
 - Richard Sterling, 2007
 - Michele Carter 2008, currently attending at Clifton T Perkins and in private practice
- 2013-2016 PGY 2 Didactics – Use of Cognitive Behavioral Therapy in Schizophrenia
1.5 hours/year

Foreign Medical Graduate

2011-2018 Saeed Ahmed, supervisor and mentor. Obtained residency in psychiatry Residency at Nassau University Medical Center, NY, completed Addiction Psychiatry fellowship at Boston University School of Medicine

Grant Support

Active Grants

- 2018-2023 (Co-Inv, 2%; PI: J. Waltz)
“Reward System Function as a Potential Mediator of the Impact of Stress on Psychopathology: A Computational Neuroimaging Study”
NIH: R01 MH115031
Direct Costs: \$1,843,673 over five years
Role: Medical support
- 2020-2023 (Co-Inv, 10%; PI: D. Kelly)
“A Randomized Controlled Trial of a Telementoring Program, Project ECHO, to Increase Clozapine Prescribing”
NIMH 1R37MH12156
Total Costs: \$3,078,526
Role: Course Instructor/Clozapine consultation and education

Active Contracts

- 2019-2021 (Medical Consultant, 20%; PI: R. Love)
“Antipsychotic Utilization Review”; State of Maryland Medical Contract (DHMH OPASS 18-17808G)
Role: Psychiatric consultant
- 2020-2025 (Medical Director, FEC, 50%; PI: R.W. Buchanan)
Agreement with Maryland Department of Health
Title: “Maryland Center for Excellence on Early Intervention Program (EIP)”
Award Amount \$8,632,885

Role: Psychiatric Consultation and Administrative support

Completed Grants

- 1996-2001 (Inv,15%, PI: R.W. Buchanan)
“Clozapine Treatment of Schizophrenic Outpatients”
NIMH R01 MH45074
\$1,386,514 total direct costs
Role: Recruitment, enrollment and medical management
- 200-2009 (Co-Inv,10%, Co-PI: D. Kelly)
“Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia”
NIDA HHSN271200599091C
\$103,501 total direct costs
Role: Study design and implementation, Residential Research Support Services
- 2008-2013 (Study Physician, 24%; PI: W.T. Carpenter)
“MPRC Centers for Intervention Development and Applied Research” (CIDAR) (NIMH 1P50 MH082999)
\$1,999,879 total direct costs
Role: Recruitment, enrollment, and medical management

Completed Contracts

- 2011-2013 (Study Physician, 5%; PI: R.W. Buchanan)
“A Randomized, Double-Blind, Parallel-Design Trial Comparing the Effects of Eltoprazine (as an Adjunctive Treatment to Anti-Psychotics) with Placebo in Adults with DSM IV/DSM IV TR Diagnosis of Schizophrenia, in Improving one or more Dimensions of Cognitive Impairment Associated with Schizophrenia”
PsychoGenics, Inc.; PGI 12004; Contract
\$117,995 total direct costs
Role: Recruitment, enrollment, and medical management
- 2013-2014 (Physician, 67%; PI: R.W. Buchanan)
Agreement with Maryland Department of Health,
Title: “Maryland Center for Excellence on Early Intervention Program (EIP)”
Role: Clinical diagnostic and management Consultation
- 2014-2020 (Physician, 50%; PI: R.W. Buchanan)
Agreement with Maryland Department of Health,
Title: “Maryland Center for Excellence on Early Intervention Program (EIP)”
- 2018-2019 (Medical Consultant, 7%; PI: R. Love)
Antipsychotic Utilization Review
State of Maryland Medical Contract, (DHMH OPASS 18-17808G)
Total budget: \$699,890

Publications

Peer Reviewed Journal Articles

1. Carpenter WT Jr, Breier A, Buchanan RW, Kirkpatrick B, Shepard P, **Weiner E**. Maziadol treatment of negative symptoms. *Neuropsychopharmacology* 23:365-374, 2000. PMID:10989263; DOI:10.1016/S0893-133X(00)00115-9.
2. **Weiner E**, Ball P, Summerfelt A, Gold J, Buchanan RW. Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. *American Journal of Psychiatry* 158(4):635-637, 2001. PMID:11282701; DOI:10.1176/appi.ajp.158.4.635.
3. Buchanan RW, Ball MP, **Weiner E**, Kirkpatrick B, Gold JM, McMahon RP, Carpenter WT Jr. Olanzapine treatment of residual positive and negative symptoms. *American Journal of Psychiatry* 162(1):124-129, 2005. PMID:15625210; DOI:10.1176/appi.ajp.162.1.124.
4. Fischer BA, **Weiner E**. Clozapine levels lowered by modafinil: A case report and brief review of modafinil in Schizophrenia. *Clinical Schizophrenia & Related Psychoses* 2(1):88-90, 2008.
5. Kelly DL, McMahon RP, **Weiner E**, Boggs DL, Dickinson D, Conley RR, Buchanan RW. Lack of beneficial galantamine effect for smoking behavior: A double-blind randomized trial in people with schizophrenia. *Schizophrenia Research* 103(1-3):161-168, 2008. PMID:18550339; PMCID:PMC2547986; DOI:10.1016/j.schres.2008.04.027.
6. Kelly DL, **Weiner E**, Ball MP, McMahon RP, Carpenter WT, Buchanan RW. Remission in schizophrenia: The relationship to baseline symptoms and changes in symptom domains during a one-year study. *Journal of Psychopharmacology* 23(4):436-441, 2009. PMID:18583442; PMCID:PMC3718069; DOI:10.1177/0269881108093883.
7. **Weiner E**, Conley RR, Ball MP, Feldman S, Gold JM, Kelly DL, Wonodi I, McMahon RP, Buchanan RW. Adjunctive Risperidone for partially responsive people with schizophrenia treated with clozapine. *Neuropsychopharmacology* 35(11):2274-2283, 2010. PMID:20664583; PMCID:PMC2939921; DOI:10.1038/npp.2010.101.
8. Mann-Wrobel M, Bennett ME, **Weiner EE**, Buchanan RW, Ball MP. Smoking history and motivation to quit in smokers with schizophrenia in a smoking cessation program. *Schizophrenia Research* 126:277-283, 2011. PMID:21112185; DOI:10.1016/j.schres.2010.10.030.
9. **Weiner E**, Buchholz A, Coffay A, Liu F, McMahon RP, Buchanan RW, Kelly DL. Varenicline for smoking cessation in people with schizophrenia: A double blind randomized pilot study. *Schizophrenia Research* 129(1):94-95, 2011. PMID:21376537; PMCID:PMC3691956; DOI:10.1016/j.schres.2011.02.003
10. **Weiner E**. Lessons from Jimmy. *American Journal of Psychiatry* 168(3):243-244, 2011. PMID:21368305; DOI:10.1176/appi.ajp.2010.10101562.
11. **Weiner E**, Ball MP, Buchholz AS, Gold JM, Evins AE, McMahon R, Buchanan RW. Bupropion sustained release added to group support for smoking cessation in schizophrenia: new randomized trial data and a meta-analysis. *Journal of Clinical Psychiatry* 73(1):95-102, 2012. PMID:21535998; DOI:10.4088/JCP.10m06143gre.
12. **Weiner E**, Ahmed S. Smoking cessation in schizophrenia. *Current Psychiatry Reviews* 9(2):164-172, 2013.

13. Buchanan RW, **Weiner E**, Kelly DL, Gold JM, Keller WR, Waltz JA, McMahon RP, Gorelick DA. Rasagline in the treatment of the persistent negative symptoms of schizophrenia. *Schizophrenia Bulletin* 41(4):900-908, 2015. PMID:25368372; PMCID: PMC4466175; DOI:10.1093/schbul/sbu151.
14. Wehring HJ, Heishman SJ, McMahon RP, Liu F, Feldman S, Raley H, **Weiner E**, Kelly DL. Antipsychotic treatment and tobacco craving in people with schizophrenia. *Journal of Dual Diagnosis* 13(1):36042, 2017. PMID:28166471; PMCID: PMC5379991; DOI: 10.1080/15504263.2017.1288946.
15. Buchanan RW, Kelly DL, **Weiner E**, Gold JM, Strauss GP, Koola MM, McMahon RP, Carpenter WT. A randomized clinical trial of oxytocin or galantamine for the treatment of negative symptoms and cognitive impairments in people with schizophrenia. *Journal of Clinical Psychopharmacology* 37(4):394-400, 2017. PMID:28590362; PMCID: PMC5484721; DOI: 10.1097/JCP.0000000000000720.
16. Wehring HJ, Buchanan RW, Feldman S, Carpenter WT, McMahon RP, **Weiner E**, Gold JM, Adams HA, Strauss GP, Rubin LH, Kelly DL. Oxytocin and sexual function in males and females with schizophrenia. *Schizophrenia Research* 199:431-432, 2018. PMID:29551232; DOI: 10.1016/j.schres.2018.03.013.
17. Dwyer KR, Andrea AM, Savage CLG, Orth RD, Shan L, Strauss GP, Adams HA, Kelly DL, **Weiner E**, Gold JM, McMahon RP, Carpenter WT, Buchanan RW, Blanchard JJ. A randomized clinical trial of oxytocin or galantamine in schizophrenia: Assessing the impact on behavioral, lexical, and self-report indicators of social affiliation. *Schizophrenia Bulletin Open* 1(1)sgaa001. PMID: 32803156; PMCID: PMC7418868; DOI: 10.1093/Schizbulletin/sgaa001.
18. Buchanan RW, **Weiner E**, Kelly DL, Gold JM, Chen S, Zaranski J, Blatt F, Wehring H, Carpenter WT. Anti-inflammatory combination therapy for the treatment of schizophrenia. *Journal of Clinical Psychopharmacology* 40(5):444-450, 2020. PMID: 32796391; DOI: 10.1097/JCP.0000000000001253.
19. Roche DJO, Bennett M, **Weiner E**. Pharmacological interventions to address cigarette smoking in people with schizophrenia spectrum disorders. *Lancet Psychiatry* 7(9):723-724, 2020. PMID: 32828151; DOI: 10.1016/S2215-0366(20)30353-9.
20. Buchanan RW, Kelly DL, Strauss GP, Gold JM, **Weiner E**, Zaranski J, Shuo C, Blatt F, Holden J, Granholm E. Combined oxytocin and CBSST for social function in people with schizophrenia. *The Journal of Clinical Psychopharmacology* 41(3):236-243, 2021. PMID: 33783399; DOI: 10.1097/JCP.0000000000001397.

Web Based Journal Articles

1. Warren KR, **Weiner E**, Kelly DL. Brief psychotic disorder. *British Medical Journal*, online monograph: <https://online.epocrates.com/u/29111118/Brief+psychotic+disorder>.

Book Chapters

1. Kelly DL, **Weiner E**, Wehring HJ. Schizophrenia. In: Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Kolesar JM, DiPiro JT (eds.), *Pharmacology Principles and Practice*, Second Edition. NY: The McGraw-Hill Companies, Inc., 2010, Section 6, Chapter 37, pp.631-652.

2. Kelly DL, **Weiner E.** Schizophrenia. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer JC, DiPiro JT (eds), *Pharmacotherapy Principles & Practice*. New York: McGraw Hill Medical, 2006, pp 549-567.

Major Invited Speeches

Local

1. Weiner, E., Can People with Schizophrenia Stop Smoking? Annual Maryland Schizophrenia Conference, Baltimore, Maryland, 2003.
2. Weiner, E., People with Schizophrenia Can Stop Smoking. Annual Maryland Schizophrenia Conference, Baltimore, Maryland, 2007.
3. Weiner, E. Adjunctive Risperidone in Clozapine Treated People with Schizophrenia. Departmental Research Day, University of Maryland School of Medicine, Department of Psychiatry, Baltimore, Maryland, 2009.

National

4. Weiner, E., Adjunctive Risperidone in Clozapine Treated People with Schizophrenia International Congress of Schizophrenia Research, San Diego, California, 2009.

Proffered Communications

1. Clinical Outcomes in a Research Clinic Population vs. A Community Mental Health Center (CMHC) Population, **E. Weiner**, J. Bisch, R.W. Buchanan, International Congress of Schizophrenia Research, Santa Fe, New Mexico, April 1999.
2. Open labeled study of bupropion SR for smoking cessation in schizophrenia. **E.E. Weiner**, M.P. Ball, R.W. Buchanan, J.M. Gold, A.T. Summerfelt, International Congress of Schizophrenia Research, British Columbia, Canada, April 2001.
3. Olanzapine treatment of residual positive and negative symptoms. R.W. Buchanan, M.P. Ball, **E. Weiner**, B. Kirkpatrick, International Congress of Schizophrenia Research, Colorado Springs, Colorado, March 2003.
4. Comparison of bupropion SR and placebo for smoking cessation in schizophrenia. **E. Weiner**, R. Buchanan, J. Gold, P. Ball, M. Bennett, International Congress of Schizophrenia Research, Colorado Springs, Colorado, March 2003.
5. The impact of smoking history and motivation to change on smoking cessation in schizophrenia. M.C., Mann, M.E. Bennett, **E. Weiner**, R.W. Buchanan, M. P. Ball. International Congress of Schizophrenia Research, Savannah, Georgia, April 2005, Schizophrenia Bulletin 31(2):205.
6. Prolactin elevation in clozapine patients treated with adjunctive risperidone. **E. Weiner**, M.P. Ball, R.W. Buchanan, R. Conley. International Congress of Schizophrenia Research, Savannah, Georgia, April 2005, Schizophrenia Bulletin 31(2):573.
7. Adjunctive risperidone in clozapine treated people with treatment-resistant schizophrenia. R.W. Buchanan, **E. Weiner**, M.P. Ball, S. Feldman, R.R. Conley, D. Kelly, J.M. Gold, R. McMahon. American College of Neuropsychopharmacology 47th Annual Meeting, Scottsdale, Arizona, December 8, 2008.

8. Metabolic side effects of combined antipsychotic treatment: Results from a double-blind trial of adjunctive risperidone in clozapine treated people with treatment-resistant schizophrenia. C.M. Richardson S. Feldman, D.L. Kelly, M.P. Ball, D.L. Boggs, **E. Weiner**, R.C. Conley, J.M. Gold, R.P. McMahon, R.W. Buchanan. International Congress of Schizophrenia Research, San Diego, California, March 28-April 1, 2009, Schizophrenia Bulletin 35(1):28, 2009.
9. Adjunctive risperidone in clozapine treated people with treatment-resistant schizophrenia. **E. Weiner**, M.P. Ball, S. Feldman, R. Conley, D. Kelly, J.M. Gold, R.P. McMahon, R.W. Buchanan. International Congress of Schizophrenia Research, San Diego, California, March 28-April 1, 2009, Schizophrenia Bulletin 35(1):358, 2009.
10. Rasagline in the treatment of the persistent negative symptoms of schizophrenia. R.W. Buchanan, **E. Weiner**, D. Kelly, R.P. McMahon, J.M. Gold, D.A. Gorelick. International Congress of Schizophrenia Research, Orlando Grande Lakes, Florida, April 21-25, 2013, Schizophrenia Bulletin 39(1):S323, 2013.
11. Oxytocin and galantamine for the treatment of negative symptoms and cognitive impairments in schizophrenia. R.W. Buchanan, D.L. Kelly, G.P. Strauss, J.M. Gold, R.P. McMahon, H.J. Wehring, **E. Weiner**, J. Osing, K.M. Sullivan, S.M. Feldman, W.T. Carpenter. 15th International Congress on Schizophrenia, Colorado Springs, Colorado, March 29, 2015.\
12. Effects of intranasal oxytocin on satiety signaling in people with schizophrenia. K.R. Warren, R.W. Buchanan, R.P. McMahon, Wehring H, A.M. Kearns, S. Feldman, C. Richardson, G. Vyas, M.M. Koola, W. Keller, P. Muhler, S. Cassell, **E. Weiner**, W.T. Carpenter, D. Kelly. 15th International Congress on Schizophrenia, Colorado Springs, Colorado, March 31, 2015.
13. Combined oxytocin and CBSST for social function in people with schizophrenia. E.L. Granholm, D.L. Kelly, G.P. Strauss, J.M. Gold, **E. Weiner**, R.P. McMahon, J.L. Holden, R.W. Buchanan. 2017 Society for Research in Psychopathology Annual Conference, Denver, Colorado, September 14-17, 2017.
14. Combined oxytocin and CBST for social function in people with schizophrenia. R.W. Buchanan, D.L. Kelly, G.P. Strauss, J.M. Gold, **E. Weiner**, R.P. McMahon, J. Holden, E. Granholm. American College of Neuropsychopharmacology 56th Annual Meeting, Palm Springs, California, December 3-7, 2017.